Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TransMedics Group, Inc.

Get SEC filing alerts via email and in your feed for TransMedics Group, Inc.

TMDX

TransMedics Group, Inc.

About TransMedics Group, Inc.

TransMedics Group, Inc. develops and commercializes advanced organ preservation and transportation systems, primarily through its FDA-approved Organ Care System (OCS) platform for heart, lung, and liver transplants. The company offers innovative solutions for organ optimization, assessment, and logistics, increasing transplant access and improving outcomes. Its business model relies on device sales, disposable sets, and comprehensive logistics services, serving transplant centers worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TransMedics Group, Inc.

1
1
TransMedics Group, Inc. TransMedics Reports 21.2% Revenue Growth to $173.9 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
TransMedics Group, Inc. TransMedics Group Reports $605.5 Million Revenue for 2025, 37.1% Increase from 2024

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
TransMedics Group, Inc. TransMedics Group Reports 32.3% Revenue Growth to $143.8 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TransMedics Group, Inc. TransMedics Group Reports 37.7% Revenue Growth to $157.4 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TransMedics Group, Inc. TransMedics Group Reports 48% Revenue Growth to $143.5 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TransMedics Group, Inc. TransMedics Reports Significant Revenue Growth and Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments